Propanc Bio Stock Price, News & Analysis

Propanc Biopharma (Nasdaq: PPCB) has provided a significant shareholder update following its successful IPO and Nasdaq uplisting. The company raised $4 million through an IPO of 1,000,000 shares at $4.00 per share, with trading commencing on August 15, 2025.

The company is preparing to advance its lead cancer treatment, PRP, into a Phase 1B First-In-Human study with 30-40 advanced cancer patients in 2026. PRP is a proenzyme mixture that acts as an EMT modulator, targeting various solid tumors. Additionally, Propanc is developing Rec-PRP, a synthetic backup compound, with pharmacology studies planned for Q1 2026.

The company has strengthened its leadership by appointing a new CFO and two Non-Executive Directors, and has raised $30 million since inception. The target market for PRP's initial indications (pancreatic and ovarian cancers) is projected to reach $18.1 billion by 2029.

Propanc Biopharma (NASDAQ: PPCB), a biopharmaceutical company focused on novel cancer treatments, has successfully completed its public offering and uplisting to the Nasdaq Capital Market. The company sold 1,000,000 shares at $4.00 per share, raising gross proceeds of $4 Million.

Trading under the symbol "PPCB" commenced on August 15, 2025, with the offering closing on August 18, 2025. The underwriters, D. Boral Capital LLC and Craft Capital Management LLC, have a 45-day option to purchase up to 150,000 additional shares at the public offering price, less underwriting discounts.

Propanc Biopharma (NASDAQ:PPCB), a biopharmaceutical company focused on novel cancer treatments, has announced its uplisting to the Nasdaq Capital Market and pricing of a $4 million public offering. The company is offering 1,000,000 shares at $4.00 per share, with an additional 45-day option for underwriters to purchase up to 150,000 shares.

Trading on Nasdaq is set to begin on August 15, 2025, transitioning from the OTC Markets Pink Tier. The offering, expected to close on August 18, 2025, will be managed by D. Boral Capital LLC and Craft Capital Management LLC. Proceeds will be used for working capital and general business purposes.

Propanc Biopharma (OTC Pink: PPCB) announced significant interest in their scientific publications on proenzymes cancer treatment. Two peer-reviewed articles reached 10 citations and 4,500 reads in August 2024. The first article, published in Scientific Reports, demonstrates the effectiveness of proenzymes in suppressing pancreatic Cancer Stem Cells. The second article highlights the anti-tumor efficacy of pancreatic proenzymes, particularly for pancreatic and ovarian cancers.

A clinical study led by Dr. Kenyon showed that 41.3% of late-stage cancer patients treated with proenzymes had significantly longer survival times than expected. With global market projections for pancreatic cancer drugs at $6.93 billion by 2030 and ovarian cancer drugs at $13.9 billion by 2029, Propanc Biopharma aims to advance its lead asset, PRP, into early-stage clinical development to address the pressing need for new therapies with fewer side effects.

Propanc Biopharma (OTC Pink: PPCB) has received a Notice of Allowance for its 'Proenzyme Composition' patent from the Canadian Intellectual Property Office. This patent broadly covers high dose and high ratio claims for future clinical doses of PRP, the company's lead asset for treating recurring and metastatic cancer. It's the second Canadian patent allowed or granted, part of Propanc's 93-patent portfolio filed in major jurisdictions. The patent is important for future clinical dosage ranges as Propanc advances towards a Phase 1 First-In-Human study in advanced cancer patients with solid tumors. PRP targets the global metastatic cancer treatment market, projected to reach $111.2 Billion by 2027. The patent has been granted in Europe, Japan, and South East Asia, and is under examination in the US.

Propanc Biopharma (OTC Pink: PPCB) announces that its lead asset, PRP, could potentially solve the problem affecting response rates of immune checkpoint inhibitors in treating PD-L1-High solid tumors. Dr. Julian Kenyon, CSO, predicts that pretreatment with PRP could reverse the promotion of epithelial to mesenchymal transition (EMT) pathways induced by PD-L1, which are responsible for tumor growth and metastasis.

The Immune Checkpoint Inhibitors Market, valued at $47.22 Billion in 2023, is expected to reach $158.26 Billion by 2031. However, response rates for most solid tumors range only between 15-30%. A recent study in the British Journal of Cancer suggests that EMT induced by tumor cell-intrinsic PD-L1 signaling predicts poor response to immune checkpoint inhibitors in PD-L1-High lung cancer.

Dr. Kenyon believes PRP could enable PD-L1 non-responders to become responders by inducing cell differentiation in cancer cells, reversing EMT pathways, and reducing metastatic potential.

Propanc Biopharma, a biopharmaceutical company, announced receiving a Certificate of Grant for its “proenzymes composition” patent from the Japanese Patent Office, marking its fourth Japanese patent. This patent covers dosing regimen claims for PRP, the company's lead asset, advancing to clinical development. Additionally, the Intellectual Property of Malaysia granted a patent for a cancer treatment using trypsinogen and chymotrypsinogen, the company's third patent in Malaysia. Propanc's intellectual property portfolio now includes 93 patents worldwide for using PRP against solid tumors. Japan's pharmaceutical market, projected to reach $46.36 billion in 2024, is a key market for Propanc. The company aims to advance PRP into a Phase 1b clinical study, targeting and eradicating cancer stem cells without severe side effects.